DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant
Status:
Terminated
Trial end date:
2021-04-05
Target enrollment:
Participant gender:
Summary
This is a proof of concept, single center study for the donation of HCV-positive hearts to
HCV negative recipient patients, with preemptive, interventional treatment with 12 weeks of
commercially available DAA therapy to prevent HCV transmission upon transplantation.